All news

Form SCHEDULE 13G REGENXBIO Inc. Filed by: JPMORGAN CHASE & CO

Alpha Vantage · StreetInsider · · AI-summarised by FinFlash

JPMorgan Chase & Co. filed a Schedule 13G with the SEC, reporting beneficial ownership of 3,560,915 shares of REGENXBIO Inc. common stock, representing 5.3% of the class. The filing indicates JPMorgan Chase & Co. has sole voting power over 3,324,340 shares and sole dispositive power over 3,560,915 shares.

Read original source

RGNX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.